At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy
In Brief
A Phase 2 clinical trial evaluating obinutuzumab, cyclophosphamide, and 3 other interventions for Lymphoma, B-Cell. Completed, enrolled 100 participants across 38 sites.
Detailed Summary
This open-label, multicenter study will evaluate the efficacy and safety of obinutuzumab \[RO5072759 (GA101)\] in combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemotherapy in patients with advanced diffuse large B-cell lymphoma. Patients will receive 8 cycles of obinutuzumab (1000 mg intravenously on Day 1 of each 21-day cycle, during Cycle 1 obinutuzumab will also be infused on Days 8 and 15) in combination with CHOP chemotherapy on Day 1 of cycles 1 to 6. A substudy will investigate the drug-drug interaction of obinutuzumab with CHOP chemotherapy agents. For the substudy, an additional cohort of approximately 15 patients are planned to be enrolled at a subset of investigational sites.
Study Details
Timeline
Interventions
1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.